All In Biotech

Drug Trial Radar · NCT07310927

Alginate vs Sucralfate for GERD Symptomatic Relief

Alginate vs Sucralfate for GERD Symptomatic Relief in Combination With PPIS

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Apr 1, 2025

Primary completion

Apr 30, 2026

Study completion Jul 13, 2026

Sponsor

Lead sponsor
CMH Lahore Medical College and Institute of DentistryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus.It can also present in an atypical manner such as chest pain, dental erosions, chronic cough, laryngitis, or asthma i.e. extra gastroesophageal symptoms. Sucralfate is a unique anti-ulcer drug and is a basic aluminum salt of sucrose octa-sulfate. It forms a protective layer, enhancing bicarbonate production, demonstrating anti-peptic properties, and fostering tissue growth, regeneration, and repair and it undergoes minimal enteral reabsorption. Alginate is a naturally occurring anionic polymer typically obtained from brown seaweed and has been extensively investigated and used for many biomedical applications, due to its biocompatibility, low toxicity, relatively low cost, and mild gelation by addition of divalent cations such as Ca2+.Both sucralfate and alginate have been in use for the treatment and symptomatic relief of GERD and are well tolerated oral formulations.

Conditions

  • GERD

Interventions

  • AlginateDrug

    2 Table spoon spoon suspension syrup twice a day before meal.

  • SucralfateDrug

    2 Table spoon spoon suspension syrup twice a day before meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality of Life in Reflux and DyspepsiaTime frame: Before Treatment, At 4 weeks, At 6 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cmh Lahore

    Lahore, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.